TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24136153

Group type: EXPERIMENTAL
Intervention: Darexaban 15 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg qd
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darexaban 60 mg qd
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg qd
Number of subjects: 0
Study: 22917830

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted apical suction (VAS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Deep pericardial traction suture (DPTS)
Number of subjects: 20
Study: 21083385

Group type: EXPERIMENTAL
Intervention: VX-770 150 mg
Number of subjects: 39
Study: 18765400

Group type: EXPERIMENTAL
Intervention: CS‐10 prepared spermatozoa
Number of subjects: 28

Group type: COMPARATOR
Intervention: DGC prepared spermatozoa
Number of subjects: 28
Study: 16404415

Group type: EXPERIMENTAL
Intervention: Plant sterol group (2 g/day)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 14974339

Group type: EXPERIMENTAL
Intervention: Angioguard coronary filter
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group without protection device
Number of subjects: 31
Study: 10862204

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with patch closure (CEAP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Carotid eversion endarterectomy (CEE)
Number of subjects: 86
Study: 9174684

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (150 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study: 1540759

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1168
Study: 4076364

Group type: EXPERIMENTAL
Intervention: 4 puffs of 50 micrograms BDP twice daily (AM/PM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 8 puffs of 50 micrograms BDP once daily (AM)
Number of subjects: 23
Study: 29915962

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin nasal spray
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 100
Study: 26465232

Group type: EXPERIMENTAL
Intervention: House dust mite sublingual immunotherapy (HDM AIT)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study: 24780180

Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Support group
Number of subjects: 115
Study: 23078375

Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no probiotic)
Number of subjects: 0
Study: 20883231

Group type: EXPERIMENTAL
Intervention: Adherent patients
Number of subjects: 434

Group type: COMPARATOR
Intervention: Nonadherent individuals
Number of subjects: 434
Study: 18691854

Group type: EXPERIMENTAL
Intervention: Epoetin delta 150 IU/kg
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Epoetin delta 300 IU/kg
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Previous Epoetin delta 150 IU/kg
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Previous Epoetin delta 300 IU/kg
Number of subjects: 313

Group type: COMPARATOR
Intervention: Previous Placebo
Number of subjects: 313
Study: 15977099

Group type: EXPERIMENTAL
Intervention: 0.2 mg cerivastatin
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 0.8 mg cerivastatin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 14654482

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolytic therapy with various plasminogen activators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing large clinical trials in acute myocardial infarction
Number of subjects: 0
Study: 10354297

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) 300 mg three times per week for eight weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no IVAA treatment)
Number of subjects: 65
Study: 7589016

Group type: EXPERIMENTAL
Intervention: 5 mg Lisinopril
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5 mg Bisoprolol
Number of subjects: 22
Study: 2013204

Group type: EXPERIMENTAL
Intervention: Ceftibuten 200 mg b.i.d.
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Ceftibuten 300 mg b.i.d.
Number of subjects: 545

Group type: COMPARATOR
Intervention: Cefaclor 500 mg t.i.d.
Number of subjects: 545
Study: 6802657

Group type: EXPERIMENTAL
Intervention: Lecithin (32 g daily, 25% phosphatidylcholine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (powdered skim milk equivalent)
Number of subjects: 16
Study: 31670874

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 9298

Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment
Number of subjects: 9298

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 9298
Study: 30156450

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 186132

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 186132

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 186132

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 186132
Study: 27007077

Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI) training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-Fidelity (LF) simulation training
Number of subjects: 20
Study: 25055558

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment (50 IU monthly for 6 months)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Traditional treatment of CHF
Number of subjects: 94
Study: 22265113

Group type: EXPERIMENTAL
Intervention: Mandatory-random student drug testing (MRSDT) implemented immediately in treatment schools
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Control group (delayed MRSDT implementation)
Number of subjects: 4700

Group type: EXPERIMENTAL
Intervention: Mandatory-random student drug testing (MRSDT)
Number of subjects: 4700
Study: 19124037

Group type: EXPERIMENTAL
Intervention: Kinetic contours with dots moving in one of two regions (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kinetic contours with dots moving in both the figure and the background (Experiment 2)
Number of subjects: 0
Study: 17963300

Group type: EXPERIMENTAL
Intervention: Peg-interferon alpha-2b treatment
Number of subjects: 49
Study: 15040823

Group type: EXPERIMENTAL
Intervention: Active devices (0.3g, 90 Hz) for 10 minutes/day, 5 days/week for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo devices for 10 minutes/day, 5 days/week for 6 months
Number of subjects: 20
Study: 12428178

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment
Number of subjects: 12124

Group type: EXPERIMENTAL
Intervention: Stunting assessment
Number of subjects: 12124

Group type: EXPERIMENTAL
Intervention: Underweight assessment
Number of subjects: 12124

Group type: EXPERIMENTAL
Intervention: Micronutrient intake assessment
Number of subjects: 12124

Group type: EXPERIMENTAL
Intervention: Dietary intake assessment
Number of subjects: 12124
Study: 9559842

Group type: EXPERIMENTAL
Intervention: Transrectal microwave hyperthermia (TMH) therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 80
Study: 7650439

Group type: EXPERIMENTAL
Intervention: Buflomedil 600 mg/day for 14 days
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo 600 mg/day for 14 days
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Buflomedil and Placebo
Number of subjects: 398
Study: 2664884

Group type: EXPERIMENTAL
Intervention: Perphenazine 16 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Perphenazine 32 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 322570

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (60 mg tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ephedrine nasal spray (positive control)
Number of subjects: 0
Study: 30913216

Group type: EXPERIMENTAL
Intervention: Community health worker managed mobile health intervention including household CVD risk assessments, electronic referral, clinical decision support, and follow-up tracking system.
Number of subjects: 62254

Group type: EXPERIMENTAL
Intervention: Community health worker managed mobile health intervention.
Number of subjects: 62254

Group type: COMPARATOR
Intervention: Control period (no intervention).
Number of subjects: 62254
Study: 28460195

Group type: EXPERIMENTAL
Intervention: Probiotic capsules (PRO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Probiotic + glutamine powder (PGLn)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No supplementation (CON)
Number of subjects: 32
Study: 25458558

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (0.9 mg/m²) in combination with pemetrexed (500 mg/m²) on day 1 of a 21-day cycle (E+P)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Pemetrexed alone (P)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate in combination with pemetrexed (E+P)
Number of subjects: 95
Study: 23954381

Group type: EXPERIMENTAL
Intervention: PCV7 booster
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPV booster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV7 and PPV
Number of subjects: 0
Study: 21865334

Group type: EXPERIMENTAL
Intervention: 0.45 g n-3 LC-PUFAs/d
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: 0.9 g n-3 LC-PUFAs/d
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: 1.8 g n-3 LC-PUFAs/d
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo (refined olive oil)
Number of subjects: 367
Study: 19217086

Group type: EXPERIMENTAL
Intervention: Secondary task (responding to a moving dot) added to the AB task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control for learning and variation of rotating the first target
Number of subjects: 0
Study: 17283559

Group type: EXPERIMENTAL
Intervention: ipratropium/xylometazoline 1.0 mg/mL
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: ipratropium/xylometazoline 0.5 mg/mL
Number of subjects: 786

Group type: COMPARATOR
Intervention: xylometazoline 1.0 mg/mL
Number of subjects: 786

Group type: COMPARATOR
Intervention: ipratropium 0.6 mg/mL
Number of subjects: 786

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 786
Study: 15522021

Group type: EXPERIMENTAL
Intervention: Cultured autologous melanocytes plus PUVA therapy (CMP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Suction blister transplantation plus PUVA therapy (SBP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cryotherapy plus PUVA therapy (CP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Only PUVA therapy (OP)
Number of subjects: 20
Study: 11454267

Group type: EXPERIMENTAL
Intervention: Educational intervention plus individual counsel
Number of subjects: 115

Group type: COMPARATOR
Intervention: Individual counsel alone
Number of subjects: 115
Study: 9492090

Group type: EXPERIMENTAL
Intervention: Piracetam (40 mg/kg/day in 2 divided doses for 2 months)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Piracetam and Placebo
Number of subjects: 76
Study: 7529507

Group type: EXPERIMENTAL
Intervention: Proviral DNA level in PBMC
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Viral RNA level in plasma
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Presence of p24 antigen in serum
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Presence of SI strains
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Correlation between proviral DNA and viral RNA levels
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Beta 2M and neopterin concentrations in serum
Number of subjects: 62
Study: 3336553

Group type: EXPERIMENTAL
Intervention: Exercising group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 0
Study: 29409327

Group type: EXPERIMENTAL
Intervention: EQUIP intervention (4 face-to-face educational sessions with a nurse)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard oncology care (control group)
Number of subjects: 69
Study: 27464024

Group type: EXPERIMENTAL
Intervention: Oral compound glycyrrhizin (OCG)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: UVB applications twice weekly
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: OCG+UVB
Number of subjects: 144
Study: 24962611

Group type: EXPERIMENTAL
Intervention: Participants who encoded scenes in the evening, slept overnight, and took a recognition test the next morning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who encoded scenes in the morning and remained awake during a comparably long retention interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups tested after a 20 min delay in the morning or evening
Number of subjects: 0
Study: 22463890

Group type: EXPERIMENTAL
Intervention: Oxandrolone, 0.1 mg/kg twice daily for 12 months
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Oxandrolone with exercise program
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 20727144

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome subjects
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physically active controls
Number of subjects: 40
Study: 18055130

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) variables including attitudes, norms, perceived behavioral control, and intentions
Number of subjects: 247
Study: 16909273

Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate (600 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dexibuprofen (400 mg)
Number of subjects: 24
Study: 12677281

Group type: EXPERIMENTAL
Intervention: Interventional hospitals
Number of subjects: 4605
Study: 11508399

Group type: EXPERIMENTAL
Intervention: Myrrh (12 mg/kg per day for 6 consecutive days)
Number of subjects: 7
Study: 9431480

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 8221370

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 147
Study: 3689630

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol hydrobromide (360 micrograms)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide (72 micrograms)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oral salbutamol sulphate (4 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oral pirenzepine hydrochloride (50 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bronchodilation (measured by sGaw and FEV1)
Number of subjects: 47
Study: 29506674

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Sham RIPC (Control)
Number of subjects: 223
Study: 27160142

Group type: EXPERIMENTAL
Intervention: Vaginal Alpha Lipoic Acid (10 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vaginal Progesterone (400 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 62
Study: 26201003

Group type: EXPERIMENTAL
Intervention: Intermittent exercise (10-min bouts, 30 min per day, three days a week for 10 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intermittent exercise
Number of subjects: 30
Study: 23551886

Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate (TU) 1,000 mg
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 20921111

Group type: EXPERIMENTAL
Intervention: Mental Health Court (MHC)
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 1047
Study: 18391342

Group type: EXPERIMENTAL
Intervention: Haptic guidance during laparoscopic simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No haptic guidance during laparoscopic simulation
Number of subjects: 0
Study: 16858076

Group type: EXPERIMENTAL
Intervention: Gas chromatography-mass spectrometry method
Number of subjects: 1
Study: 14627851

Group type: EXPERIMENTAL
Intervention: 99mTc-HMPAO lung scans
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 67Ga citrate lung scans
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison between two groups of patients (normal chest X-ray findings vs abnormal X-ray findings)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Correlation analysis between L/L ratio and GUI
Number of subjects: 21
Study: 10740355

Group type: EXPERIMENTAL
Intervention: Non-smoking curriculum (8 lessons over 4 weeks)
Number of subjects: 1956
Study: 9384462

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) at 75 mg m(‐2)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP)
Number of subjects: 38
Study: 30277538

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idasanutlin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atezolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asinercept (APG101)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 0
Study: 29472198

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC) initiated at birth or 1 hour after birth in combination with standard thermoregulation care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard thermoregulation care
Number of subjects: 0
Study: 27017366

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus- and probucol-eluting stents
Number of subjects: 3002

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents
Number of subjects: 3002
Study: 24732098

Group type: EXPERIMENTAL
Intervention: VR ACLS training with comprehensive feedback components
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: VR ACLS training with limited feedback components
Number of subjects: 148

Group type: COMPARATOR
Intervention: Traditional ACLS training (Control)
Number of subjects: 148
Study: 22070666

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Systemic chemotherapy only (Control)
Number of subjects: 20
Study: 18082510

Group type: EXPERIMENTAL
Intervention: High alpha-linolenic acid (ALA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low alpha-linolenic acid (ALA) group (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wine ethanol consumption
Number of subjects: 0
Study: 16209900

Group type: EXPERIMENTAL
Intervention: Females during early deceleration
Number of subjects: 30
Study: 14514169

Group type: EXPERIMENTAL
Intervention: Medical knowledge databases (DIMDI, OVID CD-ROM)
Number of subjects: 0
Study: 10772053

Group type: EXPERIMENTAL
Intervention: CarboMedics (CM) prosthesis
Number of subjects: 200

Group type: COMPARATOR
Intervention: Monostrut (M) prosthesis
Number of subjects: 200
Study: 8325279

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg/day for a minimum of 7 days before a second iomazenil study (Group 1, n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No clobazam (Group 2, n = 4)
Number of subjects: 14
Study: 3524843

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 150 mg/day
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 29497960

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 55
Study: 26971164

Group type: EXPERIMENTAL
Intervention: Intraoperative haemoadsorption (HA) with CytoSorb® during cardiopulmonary bypass (CPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard CPB without HA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraoperative haemoadsorption (HA) with CytoSorb®
Number of subjects: 40
Study: 23860416

Group type: EXPERIMENTAL
Intervention: Exercise training program (supervised walking or stationary cycling 3 days/week for 12 weeks, plus 2 days/week home exercise after 18 supervised sessions)
Number of subjects: 1870

Group type: COMPARATOR
Intervention: Control group (usual care without exercise training)
Number of subjects: 1870
Study: 22890119

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 286

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 286
Study: 19908060

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) bout 1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) bout 2
Number of subjects: 9
Study: 18771879

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Number of subjects: 151

Group type: COMPARATOR
Intervention: Supervised hospital-based exercise
Number of subjects: 151
Study: 16482467

Group type: EXPERIMENTAL
Intervention: BNP group (n=47)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (n=56)
Number of subjects: 103
Study: 12952269

Group type: EXPERIMENTAL
Intervention: Bosentan (add-on therapy)
Number of subjects: 20
Study: 10998773

Group type: EXPERIMENTAL
Intervention: Manual hyperinflation (MH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (non‐MH group)
Number of subjects: 100